09:45 AM EDT, 10/21/2024 (MT Newswires) -- Bright Minds Biosciences ( DRUG ) said Monday it is collaborating with Firefly Neuroscience ( AIFF ) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tolerability and efficacy of BMB-101 to treat absence epilepsy and developmental epileptic encephalopathy.

The trial is expected to enroll 20 adults from 18 to 65 years old, Bright Minds said.

Bright Minds and Firefly have previously collaborated to analyze data from the phase 1 trial of BMB-101 using Firefly's BNA technology platform, the company said.

"This compound is not only poised to make a significant impact in both the [developmental epileptic encephalopathy] and absence epilepsy communities, but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance," said Ian McDonald, Bright Minds chief executive .

Bright Minds shares rose 24% in early trading, while Firefly was up 17%.

Price: 58.74, Change: +11.53, Percent Change: +24.42